The US Food and Drug Administration has approved a new drug to treat patients with multidrug-resistant HIV-1, the first therapy in more than a decade with a new mechanism of action. Developed by Taipei, Taiwan–based TaiMed Biologics, Trogarzo (ibalizumab-uiyk) is a humanized monoclonal antibody that binds… Para acessar a publicação na íntegra clique aqui Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 4 APRIL 2018 291…
FDA approves strokedetecting AI software
The US Food and Drug Administration (FDA) has cleared a deep-learning algorithm that analyzes images to detect potential strokes. The computer-aided image software system from San Francisco-based AI-health firm Viz.ai, identifies suspected large vessel… Para acessar a publicação na íntegra clique aqui Fonte: VOLUME 36 NUMBER 4 APRIL 2018 NATURE BIOTECHNOLOGY …
Nature Biotechnology’s academic spinouts of 2017
2017 was a good year for biotechs looking to raise money. Venture capital investment in biotech companies reached the stratospheric levels of $16 billion. And it was not only seasoned companies that benefitted—the largesse extended to companies raising their first rounds, which accounted for nearly a third of risk capital entering the sector. Para acessar a publicação na íntegra clique aqui Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 4 APRIL 2018…
CIEnP realiza minicurso sobre “NONCLINICAL SAFETY EVALUATION”.
No dia 5 de abril de 2018 foi realizado no CIEnP um minicurso sobre desenvolvimento pré-clínico de medicamentos ministrado pelo Professor Ernie Harpur B.Sc., Ph.D., FATS, FBTS, FRSB Newcastle University, UK. O Dr Harpur é um destacado pesquisador na área de estudos pré-clínicos para desenvolver novos medicamentos, com grande experiencia na área tendo trabalho por várias décadas nas maiores companhias farmacêuticas globais tanto na Inglaterra como nos Estados Unidos. Atualmente o professor Harpur é o presidente da Sociedade de Toxicologia…
Top drugs and companies by sales in 2017
A look at the best-selling drugs in 2017 shows the top spots dominated by monoclonal antibodies which, despite their age and looming competition, are still pulling in billions of dollars (FIG. 1a). The success of these huge franchises is partly down to the ability of manufacturers to continue to raise prices in the United States, even on these long-established assets, while… Para acessar a publicação na íntegra clique aqui Fonte: 232 | APRIL 2018 | VOLUME 17 www.nature.com/nrd…
Upcoming market catalysts in Q2 2018
Potential market catalysts in the second quarter of 2018 include top-line clinical trial results for NEOD001 (developed by Prothena) for light-chain (AL) amyloidosis and ALXN1210 (developed by Alexion) for paroxysmal nocturnal haemoglobinuria (PNH), as well as an FDA advisory committee meeting on volanesorsen (developed by Akcea Therapeutics) for familial chylomicronaemia syndrome (FCS)… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | APRIL 2018 | 233 …